Specifically, it has been suggested that defective anti-tumor immune responses frequently seen in patients with advanced cancers are driven by TEX and may be responsible for tumor immune escape, unresponsiveness to IT, and resistance of tumors to oncological therapies [6,7,8]. Here, TEX46 is linked to cancer.